NCT04634799

Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

Enrollment challenges; new batch of drug is being manufactured and there may be additional impetus to reactivate after the analogous Phase 2 study in Japan is completed and those results are made available